B. Protocoles,

, A cette solution, on ajoute la benzylamine (4,33 mL, 39,7 mmol) ainsi que la TEA (14,5 mL, 104 mmol). Le mélange est chauffé au reflux du n-BuOH pendant 3 heure. Par filtration sous vide puis rinçage au n-BuOH froid (2 x 10 mL), le produit 1 est récupéré sous forme de poudre blanche, On dissout la 2,6-dichloro-9H-purine (5 g, 26 mmol) dans le n-BuOH (40mL), vol.46

, Masse molaire : 259,69 g / mol Aspect : poudre blanche Rdt moyen : 96 %

, DMSO-d6): ? 4.63 (d, 2H, J = 5.2 Hz, CH2-NH), vol.7

R. Dept, CH2); pour : -5 g de 2,6-dichloro-9H-purine : Rdt = 92 % -15 g de 2,6-dichloro-9H-purine : Rdt = 98 % -15 g de 2,6-dichloro-9H-purine : Rdt = 96, vol.2

. Methyl, g / mol Aspect : poudre blanche hygroscopique Point de fusion, p.62

, CH3-CH2-CH,); 0.80 (d, 6H, J = 6.8 Hz, (CH3)2-CH-CH,); 1.40 (s, 6H, (CH3)2-CH-NH), RMN 1 H (DMSO-d6): ? 0.75 (d, 3H, J = 6.4 Hz, vol.1

R. Dept, DMSO-d6): ? 17.68, vol.18, p.50

. On-applique-le-protocole-e-pour, g de (S)-CR8 et 0,591 g de Val Chloro Phosphorochloridate pour obtenir 0,027 g de CR8 Val H, vol.25

, BIBLIOGRAPHIE

N. O. Bukanov and S. E. Moreno, CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD

T. A. Natoli, K. A. Rogers, L. A. Smith, S. R. Ledbetter, N. Oumata et al., Cell Cycle, vol.11, issue.21, pp.4040-4046, 2012.

B. Cheong, R. Muthupillai, M. F. Rubin, and S. D. Flamm, Normal Values for Renal Length and Volume as Measured by Magnetic Resonance Imaging, Clin. J. Am. Soc. Nephrol, vol.2, pp.38-45, 2007.

M. Büchler, D. Chauveau, C. Ferec, M. F. Gagnadoux, E. Genin et al., , vol.3, 2017.

F. Association-polykystose, Connaître la polykystose

U. Adresse,

, Département de médecine, service de néphrologie

, Le système Rénine-Angiotensine-Aldostérone, 2018.

U. Adresse,

P. Cochat and . Université-de-lyon, Site du, 2018.

U. Adresse,

F. Association-polykystose, Le diagnostic de PKD

U. Adresse,

C. Antignac, Université Paris Descartes, Site de l'INSERM

U. Adresse,

B. Moulin and M. N. Peraldi, Polykystose rénale. Ellipses, éditeur. Réussir l'ECN, 7 ème édition, pp.267-277, 2016.

H. Autorité-de-santé, JINARC (tolvaptan), antagoniste de la vasopressine

U. Adresse,

. Vidal, JINARC (tolvaptan) : premier médicament dans la prise en charge de la PKRAD

U. Adresse,

. Vidal,

U. Adresse,

R. Baum and S. Borman, Marcus wins chemistry Nobel. Two biochemists take medicine prize, Chem. Eng. News, vol.70, pp.6-7, 1992.

A. Payen and J. F. Persoz,

, Mémoire sur la diastase, les principaux produits de ses réactions et leurs applications aux arts industriels, Annales de chimie, pp.73-92

U. Adresse,

, The protein kinase complement of the human genome

. B. Whyted, R. Martinez, T. Hunter, and S. Sudarsanam, Science, vol.298, pp.1912-1946, 2002.

, The nobel prize in physiology or medicine, 2001.

U. Adresse,

K. Vermeulen, D. R. Van-bockstaele, and Z. N. Berneman, The cell cycle : a review of regulation, deregulation and therapeutic targets in cancer, Cell Cycle, vol.36, pp.131-180, 2003.

P. J. Nelson and S. J. Shank, Therapeutics in Renal Disease : The Road Ahead for Antiproliferative Targets, vol.1, pp.6-15, 2006.

;. Cdk5, L. H. Tsai, M. S. Lee, and J. Cruz, Alzheimer's disease ?, Biochim. Biophys. Acta, vol.1697, pp.137-179, 2004.

J. Y. Blay, L. Cesne, and A. , Le cancer : nouvelles données, nouvelles stratégies, nouveaux espoirs. ; 18 mars, vol.8, pp.53-58, 2004.

U. Adresse,

, A minute chromosom in human chronic granulocytic leukemia. Nowell P.C. ; Hungerford D. ; Science, 142, p.1497, 1960.

. Pharmacology, E. Buchdunger, T. O'reilly, J. Wood, and . Eur,

, J. Cancer, vol.38, issue.suppl5, pp.28-36, 2002.

J. Zimmermann, P. Furet, and E. Buchdunger, STI571 : a New Treatment Modality on CML ?, pp.245-259, 2001.

, La résistance à l'imatinib dans la leucémie myéloïde chronique : Etude des mécanismes moléculaires. Pocaly, M. ; Thèse pour le Doctorat de l'Université de Bordeaux 2, p.1486, 2007.

, Résistance à l'imatinib mésylate par mutation Bcr-Abl au cours de la leucémie myéloïde chronique, vol.13, pp.457-464, 2007.

. Sunitinib, M. Atkins, C. A. Jones, and P. Kirkpatrick, Nature reviews Drug Discovery, vol.5, pp.279-280, 2006.

, Nilotinib : a novel, selective tyrosine kinase inhibitor, Semin. Oncol, p.467, 2011.

. Dasatinib, H. Kantarjian, E. Jabbour, J. Grimley, and P. Kirkpatrick, Nature reviews Drug Discovery, vol.5, pp.717-718, 2006.

L. Meijer, A. Borgne, O. Mulner, J. P. Chong, J. J. Blow et al., Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5, Eur. J. Med. chem, vol.243, pp.527-563, 1997.

L. Meijer and E. Raymond, Roscovitine and others purines as kinase inhibitors. From starfish oocytes to clinical trials, Acc. Chem. Res, vol.36, issue.6, pp.417-442, 2003.

. C. Baguleyb and D. J. Kerr, Anticancer Drug Development, 2001.

V. Preclinical-studies-of-roscovitine, , 2005.

U. Adresse,

, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

F. Lombardo, B. W. Dominy, and P. J. Feeney, Advanced drug delivery reviews, vol.23, pp.3-25, 1997.

L. Havlí?ek and J. Hanu?, Cytokinin-derived cyclin-dependent kinase inhibitors : synthesis and cdc2 inhibitory activity of olomoucine and related compounds

J. Veselý, S. Leclerc, L. Meijer, G. Shaw, and M. Strnad, J. Med. Chem, vol.40, pp.408-412, 1997.

P. Traxler, G. Bold, E. Buchdunger, G. Caravatti, P. Furet et al., Tyrosine kinase inhibitors : from rational design to clinical trials, vol.21, pp.499-512, 2001.

, Roscovitine targets, protein kinases and pyridoxal kinase

M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt, B. Baratte et al.,

F. Totzke, C. Schächtele, A. S. Lerman, A. Carnero, Y. Wan et al., J. Biol. Chem, vol.280, pp.31208-31227, 2005.

I. T. Seliciclib-in-malignancies.-aldoss, T. Tashi, and A. K. Ganti, Expert Opinion on Investigational Drugs, vol.18, issue.2, 2009.

N. Oumata, K. Bettayeb, Y. Ferandin, L. Demange, and -. Lopez, Roscovitine-derived, dual specificity inhibitors of cyclin-dependent kinases and casein kinases 1
URL : https://hal.archives-ouvertes.fr/hal-00319796

A. Giral, M. L. Goddard, V. Myrianthopoulos, E. Mikros, M. Flajolet et al., J. Med. Chem, vol.51, pp.5229-5271, 2008.

K. Bettayeb, N. Oumata, A. Echalier, Y. Ferandin, J. A. Endicott et al., CR8, a potent and selective, roscovitine-derived inhibitor of cyclindependent kinases, Oncogene, vol.27, pp.5797-5807, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00319794

H. Husson, S. Moreno, L. A. Smith, M. M. Smith, R. J. Russo et al.,

S. R. Ledbetter, N. O. Bukanov, M. Lane, K. Zhang, K. Billot et al.,

L. Meijer, D. R. Beier, and O. Ibraghimov-beskrovnaya, Human Molecular Genetics, vol.25, issue.11, pp.2245-2255, 2016.

, The therapeutic Potential of Candoxatril, a Neutral Endopeptidase Inhibitor, Cardiovascular Drug Review, vol.18, issue.4, pp.259-270, 2000.

. Valaciclovir, A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infection, Perry C.M., Faulds D, vol.52, pp.754-72, 1996.

M. Ehrnebo, N. Sten-ove, and L. O. Boréus, Pharmacokinetics of amipicillin and its prodrugs bacampicillin and pivampicillin in man, vol.7, pp.429-51, 1979.

S. Santra, C. Kaittanis, O. J. Santiesteban, and J. Perez, Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy, J. Am. Chem. Soc, vol.133, pp.16680-16688, 2011.

, Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug Release

X. Zhao, J. Chen, J. Chen, L. Kuznetsova, S. S. Wong et al., Bioconjug. Chem, vol.21, pp.979-87, 2010.

D. A. Smith, Metabolism, Pharmacokinetics, and Toxicity of Functional Groups : Impact of the Building Blocks of Medicinal Chemistry in ADMET

C. S. Chen, J. T. Lin, K. A. Goss, Y. A. He, J. R. Halpert et al., Activation of the anticancer prodrugs cyclophosphamide and ifosfamide : identification of cytochrome P4520 2B enzyme and site-specific mutants with improved enzyme kinetics, Mol. Pharmacol, vol.65, pp.1278-85, 2004.

, Studies on the mechanism of absorption of depot neuroleptics : fluphenazinedecanoate in sesame oil, Pharm. Res, vol.14, pp.1079-84, 1997.

R. B. Silverman and M. W. Holladay, The Organic Chemistry of Drug Design and Drug Action, 2014.

C. Mcguigan, S. A. Harris, S. M. Daluge, K. S. Gudmundsson, E. W. Mclean et al., Application of Phosphoramidate Pronucleotide Technology to Abcavir Leads to a Significant Enhancement of Antiviral Potency, J. Med. Chem, vol.48, pp.3504-3515, 2005.

C. Mcguigan, P. Murziani, M. Slusarczyk, B. Gonczy, J. Vande-voorde et al., Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside, J. Med. Chem, vol.54, pp.7247-7258, 2011.

, Application of ProTide Technology to Gemcitabine : A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC1031) in Clinical Development

J. Balzarini, M. Mason, W. G. Jiang, S. Blagden, E. Thompson et al., J. Med. Chem, vol.57, pp.1531-1542, 2014.

, Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides

M. Derudas, N. Hamon, L. Hinsinger, S. Kandil, K. Madela et al., Eur. J. Med. Chem, vol.70, pp.326-340, 2013.